Active Ingredient History
Seribantumab is a monoclonal antibody designed for the treatment of cancer. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma (Phase 2)
Bile Duct Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Ovarian Epithelial (Phase 2)
Cholangiocarcinoma (Phase 2)
Colorectal Neoplasms (Phase 2)
Esophageal Neoplasms (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Gallbladder Neoplasms (Phase 2)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 2)
Kidney Neoplasms (Phase 2)
Lung Neoplasms (Phase 2)
Neoplasms (Phase 2)
Neuregulin-1 (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Prostatic Neoplasms (Phase 2)
Sarcoma (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 1)
Triple Negative Breast Neoplasms (Phase 1)
Urinary Bladder Neoplasms (Phase 2)
Uterine Neoplasms (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue